short answer like drug always potential problem practicing physician realizes drug approved fda general release public kinds unintended consequences possible basis post marketing surveillance fda invariably lot hype associated release drug i previously pointed fdas approval process place guarantee drug safe everyone focused releasing drug potential tool responsible practitioners means drug potentially cause small number serious unexpected reactions liver failure cardiac arrhythmia even experienced practitioners able predict also implicit understanding practitioners prescribing drug thorough understanding pharmacology indications contraindications many practitioners advise trying product released advice tempered severity individual circumstances hope relief also general bias new drugs somehow better old ones bias repeatedly disproven suboxone prescribers take special course order get prescriber number addition usual dea number i took suboxone prescriber course years ago total hours lectures given convention center room hotel jointly sponsored state medical association morning sessions largely review pharmacology drug scope opioid addiction problem time afternoon session focused vignettes patients addictions varying complexities exercise determine suboxone prescribed person induction would done first suggestion something problematic apparently contraindications suboxone clear message given anyone opioid addiction matter social circumstances comorbid psychiatric diagnoses addictions definite implication drug would revolutionize treatment opioid addiction suboxone combination buprenorphine naloxone buprenorphine active ingredient terms treating addiction post i use suboxone buprenorphine interchangeably pharmacological properties buprenorphine interesting terms potential use addiction included fact opioid mu receptor partial agonist antagonist kappa receptor partial agonist effects relevant addiction euphoria sedation occur lower doses antagonist effects occur higher doses antagonist effects like preventing respiratory depression thought put ceiling effect side effects make safer pure mu receptor agonists would produce dose related toxicities suboxone course mixed agonist antagonist effects described producing less toxicity less risk abuse naloxone component suboxone pure mu receptor antagonist course i took explanation combination buprenorphine naloxone reduced risk intravenous drug use occurred europe resulted several deaths company also sold subutex buprenorphine indicated use pregnant women pharmacodynamics pharmacokinetics real life differ quite bit idealized cases initial marketing advertising based upon like many medications life changing drug people recover break cycle addiction recovery relapse go productive lives outliers physicians need concerned real life always going people get significant side effects even low doses tolerate drug also people tolerate drug high doses experience ceiling effect mu receptor antagonism people probably low number significant protected ceiling effect supposed drug drug addiction always attracts produces significant number people become amateur pharmacologists use drug facilitate addiction word gets suddenly buprenorphine street value month prescription opioid addicts use run heroin oxycodone people preferred opioid longer half life politics suboxone complicated find pharmaceutical industry plenty conflicts interest terms drug initially marketed plenty crossover regulators company developed marketed sold reckitt benckiser according new york times article last fall company granted period exclusive sales ended went offensive suggest new product suboxone film superior generic tablets especially area child safety stopped selling suboxone tablets point insurance companies work controversy advantage people buprenorphine maintenance cut based solely amount time taking drug scientific guidelines long person take buprenorphine like drugs used maintenance therapy never study looks question due expense experts would agree severe addiction recovered based buprenorphine reason would cut fact discontinuing buprenorphine seems present significant problem dose tapered mg lower also familiar political theme issue opioids government seeming create problems first place saying trust solution may explained desperation descriptions public health officials trying increase suboxone prescribers address public health opioid epidemic likely result government initiatives improve treatment pain suboxone become problem reason every drug becomes problem unrealistic expectations conflicts interest knowledge deficit part practitioners title new york times article illustrates press look dual nature drugs imply larger problem i know two many drugs dark side negative trends buprenorphine use reversed take suggested strategy ny times article ideas cdc needs get involved look suboxone buprenorphine related deaths study manner studied methadone would instructive see exactly suboxone buprenorphine falls spectrum deaths kg mme milligram morphine equivalents expectation article much safer i would prefer see numbers cdc access detailed data look issue i would take step farther suggest cdc recalculate table annual basis key metric reversing significant public health problem accidental opioid overdose deaths physicians prescribing buprenorphine need highly motivated well versed prescribing medications individuals addictions ny times article suggests many take entrepreneurial approach prescription buprenorphine cash practices vary visit i problem cash practices quality approach definition involves lot handing someone prescription minutes problem rest happens time poorly defined original prescribing information said physician needed refer patient counseling services many presentations research i seen clear movement illustrate counseling adds little nothing outcomes buprenorphine prescribed problems drawing conclusion research given modest outcomes buprenorphine treatment least part interview patient recovering severe addiction occurs opioids assessing functional capacity day day basis routine consistent recovery lack cognitive side effects buprenorphine able corroborate improvement third party makes even reliable big part unconscious aspects addiction behaviors present continue addiction despite best conscious efforts person affected good examples include craving lying hiding use others requires prescribing physicians engage patients level develop law enforcement transference lot physicians know respond accusation trust me question need toxicology screen discussion positive toxicology interpersonal aspect treatment important received attention standard suboxone prescribing course continued work model treatment looking potential positive factors needed nothing worse medicine treat scientific topic like political one rational approach person problem like original course i took people say buprenorphine prescribed physicians office needed case person takes two three times prescribed amount get high person crushing snorting injecting person selling street get purchase heroin person ca function due cognitive problems mg day person hospitalized recurrent bowel obstructions due severe constipation prescribing physician confident accurately screen problems competing approaches like long acting mu antagonist naltrexone injections step recovery like narcotics anonymous fit sober housing residential treatment fit finally person get detoxified anyone forced go acute opioid withdrawal incarcerated questions currently unanswered like treatments medicine solution typically lot pill drugs addictive potential always add complication significant financial gain captive audience george dawson md dfapa deborah sontag addiction treatment dark side new york times november samhsa clinical guidelines use buprenorphine treatment opioid addiction treatment improvement protocol tip nice naltrexone management opioid dependence nice methadone buprenorphine management opioid dependence